Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA5A | P35218 | 3/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16220811 | 0.87 | PTGS2 (0.72) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL18031098 | 0.85 | S1PR1 (0.60) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL12420291 | 0.85 | S1PR1 (0.59) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL19186826 | 0.84 | FLT3 (0.70) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL12420391 | 0.83 | STS (0.59) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL23557718 | 0.80 | PTGS2 (0.63) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL18031100 | 0.80 | PTGS2 (0.63) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL28068164 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL28337478 | 0.80 | FLT3 (0.65) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL12420293 | 0.78 | HSD17B1 (0.56) | CA1CA2S1PR1FLT3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | PTGS2 481/4885PTGS1 440/4885CA1 4087/4885 |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | PTGS2 481/4885PTGS1 440/4885CA1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.